Source: Cloud DX.
  • Cloud DX (CDX) has extended its remote patient monitoring contract with an Ontario hospital
  • The contract will cover surgical patients until October 2025
  • The contract marks the 27th signed agreement for Cloud DX in 2022, up by 225 per cent from 2021
  • Cloud DX provides a digital and virtual health care platform for remote patient monitoring, ageing in place and hospital-quality post-surgical care
  • Cloud DX (CDX) is up by 7.14 per cent trading at $0.15 per share

Cloud DX (CDX) has extended its remote patient monitoring contract with an Ontario hospital.

The contract will cover surgical patients until October 2025.

The hospital is one of eight acute care hospitals in Canada involved in a national virtual care study to remotely manage patients after surgery. Results to date include the prevention and resolution of 24-per-cent more medication errors, with patients reporting 10-14 per cent less pain, as well as re-admission reductions of 5 per cent.

Management sees Ontario hospitals expanding the use of remote patient monitoring (RPM) to ease current surgical backlogs, EMS and ER strains, and other pressures within the province’s health care systems.

The contract marks the 27th signed agreement for Cloud DX in 2022, up by 225 per cent from 2021.

“Cloud DX is incredibly committed to partnering with hospitals across Canada to reduce surgical backlogs and system strains,” stated Robert Kaul, Cloud DX’s Founder and CEO. “Our Connected Health platform and RPM solution provide post-surgical patients tremendous peace of mind while keeping hospital beds available for other patients, especially crucial now with the increase in COVID, flu, and RSV cases we’re seeing this winter.”

Cloud DX provides a digital and virtual healthcare platform for remote patient monitoring, ageing in place and hospital-quality post-surgical care.

Cloud DX (CDX) is up by 7.14 per cent, trading at $0.15 per share as of 11:45 am ET.


More From The Market Online
Medical technician looking into a microscope

Theralase’s bladder cancer drug under investigation in clinical study

Pharma stock Theralase Technologies (TSXV:TLT) announces a significant update on its ongoing bladder cancer clinical study.
Northstar Gold worker surveying a dig site.

The best junior gold stocks take advantage of partnerships like this

Northstar Gold (CSE:NSG) signed two non-binding memorandums of understanding that are a pivotal first step to advancing their business.